SGMO — Sangamo Therapeutics, Inc.

SGMO Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Sangamo Therapeutics raised over $130 million in funding during 2025 through nondilutive license fees, milestone payments, and equity financing.
• The company is actively managing its cash runway and seeking additional funding to ensure operational continuity and support its pipeline initiatives.

2. Strategic Updates and Business Highlights

• Positive top-line results were reported from the registrational STAAR study for ST-920, a gene therapy for Fabry disease, with a favorable mean annualized eGFR slope at 52 weeks.
• The rolling submission of a Biologics License Application (BLA) for ST-920 is in progress, with the nonclinical and clinical modules submitted to the FDA.
• Sangamo transitioned to a clinical-stage neurology company, activating six clinical sites for the Phase I/II STAND study in chronic neuropathic pain.
• The company received Fast Track designation from the FDA for ST-503, an epigenetic regulator for small fiber neuropathy, highlighting the high unmet medical need in this area.
• Sangamo announced a third licensing agreement for its neurotropic capsid technology with Eli Lilly, further establishing its position in the neurology space.

3. Forward Guidance and Outlook

• The company anticipates completing the BLA submission for ST-920 by summer 2026, contingent on securing adequate funding.
• Continued engagement with potential commercial partners for Fabry disease is a priority, with ongoing discussions aimed at finding a suitable partner.

4. Bad News, Challenges, or Points of Concern

• The timeline for the BLA submission has been impacted by the need to complete Chemistry, Manufacturing, and Controls (CMC) activities, which are critical for the filing.
• There is frustration regarding the length of time taken to secure a commercial partner for Fabry disease, with previous partners dropping out due to regulatory uncertainties.
• The company faces ongoing regulatory and market uncertainties that could impact its operations and strategic initiatives.

5. Notable Q&A Insights

• Management confirmed that CMC activities are the primary gating factor for the BLA submission, emphasizing careful management of cash and spending.
• Discussions with potential partners for Fabry disease are ongoing, with new counterparties involved due to previous partners exiting discussions.
• The company is not planning additional interactions with the FDA until the BLA submission is complete, as they feel they have sufficient guidance to proceed.

This summary encapsulates the key points from Sangamo Therapeutics' Q4 2025 earnings call, highlighting both achievements and challenges as the company navigates its pipeline and funding landscape.